EuroCetus B.V. has received approval in Italy to marketCardioxane, an adjunct therapy for use against cardiac sideeffects induced by anthracycline chemotherapeutics in cancerpatients. It is the first marketing approval for the product.

Anthracycline-induced cardiotoxicity is relatively common.Doxorubicin and epirubicin, the most commonly prescribedanthracyclines, are widely used against cancers. Breast canceris a particular target, as are ovarian cancer, lymphomas,sarcomas, lung cancers, gastrointestinal cancers and certainpediatric tumors.

EuroCetus, based in Amsterdam, the Netherlands, is a unit ofChiron Corp. of Emeryville, Calif. Chiron acquired Cardioxane inits acquisition of Cetus Corp. Chiron shares (NASDAQ:CHIR)closed at $50.50, up 75 cents.

(c) 1997 American Health Consultants. All rights reserved.